<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127622">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01726075</url>
  </required_header>
  <id_info>
    <org_study_id>4C-2011-02</org_study_id>
    <secondary_id>2012-001200-38</secondary_id>
    <nct_id>NCT01726075</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy</brief_title>
  <acronym>EUROCONDOR</acronym>
  <official_title>Neurodegeneration as Early Event in Pathogenesis of Diabetic Retinopathy: Multicentric, Prospective, Ph. II-III,Random.Controlled Trial to Assess Efficacy of Neuroprotective Drugs Administered Topically to Prevent /Arrest Diabetic Retinopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BCN Peptides</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BCN Peptides</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: Ethics Committee</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>Portugal: Ethics Committee for Clinical Research</authority>
    <authority>Germany: Ministry of Health</authority>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether neuroprotective drugs administered topically (somatostatin and
      brimonidine) are able to prevent or arrest the development and progression of
      neurodegenerative changes
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Changes in the Implicit Time assessed by mfERG (IT-mfERG)at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Implicit Time assessed by mfERG (IT-mfERG)at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Implicit Time assessed by mfERG (IT-mfERG)at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Implicit Time assessed by mfERG (IT-mfERG)at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Implicit Time assessed by mfERG (IT-mfERG)at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Nerve Fiber Layer (RNFL) assessed by Spectral Domain Optical Coherence Tomography (SD-OCT) at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Nerve Fiber Layer (RNFL) assessed by SD-OCT at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Nerve Fiber Layer (RNFL) assessed by SD-OCT at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Nerve Fiber Layer (RNFL) assessed by SD-OCT at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Nerve Fiber Layer (RNFL) assessed by SD-OCT at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganglion Cell Layer (GCL) assessed by SD-OCT at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganglion Cell Layer (GCL) assessed by SD-OCT at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganglion Cell Layer (GCL) assessed by SD-OCT at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganglion Cell Layer (GCL) assessed by SD-OCT at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganglion Cell Layer (GCL) assessed by SD-OCT at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microaneurysm turnover assessed by Colour Fundus Photography (CFP - 45º/50º Field 2) at baseline</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microaneurysm turnover assessed by Colour Fundus Photography (CFP - 45º/50º Field 2) at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microaneurysm turnover assessed by Colour Fundus Photography (CFP - 45º/50º Field 2) at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microaneurysm turnover assessed by Colour Fundus Photography (CFP - 45º/50º Field 2) at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microaneurysm turnover assessed by Colour Fundus Photography (CFP - 45º/50º Field 2) at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness assessed by SD-OCT at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness assessed by SD-OCT at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness assessed by SD-OCT at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness assessed by SD-OCT at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness assessed by SD-OCT at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness assessed by SD-OCT at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness assessed by SD-OCT at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness assessed by SD-OCT at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness assessed by SD-OCT at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness assessed by SD-OCT at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Retinopathy (DR) severity assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) scale CFP - 30º/35º-7 fields at baseline</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DR severity assessed by ETDRS scale CFP - 30º/35º-7 fields at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Best Corrected Visual Acuity (BCVA) assessed by ETDRS scale at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>BCVA assessed by ETDRS scale at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>BCVA assessed by ETDRS scale at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>BCVA assessed by ETDRS scale at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>BCVA assessed by ETDRS scale at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Visual Fields defects assessed by Visual Fields Test at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Visual Fields defects assessed by Visual Fields Test at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Visual health assessed by Visual Function Questionnaire (VFQ-25) at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Visual health assessed by Visual Function Questionnaire (VFQ-25) at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events assessed by inquiry at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events assessed by inquiry at month 3</measure>
    <time_frame>month 3</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events assessed by inquiry at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events assessed by inquiry at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events assessed by inquiry at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events assessed by inquiry at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 0</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 3</measure>
    <time_frame>month 3</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 6</measure>
    <time_frame>month 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 12</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 18</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 24</measure>
    <time_frame>month 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>COLIRIOBCN070660</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution. One drop/eye administered twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Eye drops, solution. One drop/eye administered twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COLIRIOBCN070660</intervention_name>
    <description>One drop per eye twice a day during 24 months</description>
    <arm_group_label>COLIRIOBCN070660</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One drop per eye twice a day during 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine</intervention_name>
    <description>One drop per eye twice a day during 24 months</description>
    <arm_group_label>Brimonidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with type 2 diabetes mellitus

          2. Diabetes duration ≥ 5 years

          3. Aged between 45-75 years-old

          4. ETDRS level &lt; 20 (microaneurysms absent) (50% of enrolled patients) Or ETDRS levels
             20 or 35 with presence of at least one microaneurysm in Field 2 between the superior
             and inferior arcades (50% of enrolled patients) in the Study Eye as determined by the
             Reading Centre.

          5. Informed Consent

        Exclusion Criteria:

          1. Previous laser photocoagulation

          2. Other diseases which may induce retinal degeneration (e.g. glaucoma)

          3. Subject with a refractive error ≥ ± 5 diopter

          4. Inadequate ocular media and/ or pupil dilatation that do not permit good quality
             fundus photography.

          5. Renal failure (creatinine &gt; 1.4 mg/dl)

          6. HbA1C &gt; 10 % in the previous 6 months and at Screening

          7. Subjects taking somatostatin or brimonidine, for any indication, in the previous 3
             months

          8. Subject has a condition or is in a situation which may put the subject at significant
             risk, may confound the study results or may interfere significantly with the
             patient's participation in the study.

          9. Pregnancy or nursing

         10. Hypersensitivity to the active substances to be tested or to any of the excipients

         11. Subject receiving systemic monoamine oxidase (MAO) inhibitor therapy or
             antidepressants which affect noradrenergic transmission (e.g. tricyclic
             antidepressants and mianserin)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Cunha-Vaz, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association for Innovation and Biomedical Research on Light and Image</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Syddansk Universitet (SDU)</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP - Hopitaux de Paris (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Ulm (UUlm)</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Vita-Salute San Raffaele (USR)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Study di Padova(UPadova)</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aibili - Cec</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala de la Salut - Hospital Universitari Vall d'Hebron (ICS-HUVH)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Foundation Trust (CHGH)</name>
      <address>
        <city>Cheltenham</city>
        <state>Gloucestershire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aston University (UAston)Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Liverpool (UOL)</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust (MEH)</name>
      <address>
        <city>London</city>
        <zip>EC1V2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic retinopathy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brimonidine</mesh_term>
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
